Evaluating a new treatment approach for atrial fibrillation using renal artery denervation.
Official title: A Trial to Evaluate Renal Artery Denervation in Addition to Catheter Ablation to Eliminate Atrial Fibrillation (ERADICATE-AF II)
Funded at University of Rochester · NIH-10685356 · Data updated 2026-11-12
This study is looking at whether combining a procedure called renal artery denervation with catheter ablation can help people with atrial fibrillation have better heart rhythm control and fewer episodes of AF.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | September 1, 2021 |
| Project end | July 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $236,758 |
| NIH project number | 5R34HL153579-03 |
| Project ID | NIH-10685356 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with paroxysmal atrial fibrillation who are considering catheter ablation.
✕Less likely to help
Patients with persistent atrial fibrillation or those who have not responded to previous ablation therapies may not benefit from this research.
What this research studies
This research investigates the effectiveness of combining renal artery denervation (RDN) with catheter ablation to treat atrial fibrillation (AF). The study aims to determine if reducing sympathetic nerve stimulation through RDN can enhance the success of pulmonary vein isolation, a common procedure for AF. Patients participating in this trial will undergo both RDN and catheter ablation, with their heart rhythms monitored over time to assess improvements. The research builds on previous findings that suggest this combination may significantly reduce the recurrence of AF.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with atrial fibrillation, potentially reducing the need for multiple procedures.
How similar studies have gone: Previous studies, including the ERADICATE-AF trial, have shown promising results with similar approaches, indicating a potential for success.
Where this research is happening
-
University of Rochester
Rochester, United States Active
Researchers
- Principal investigator: Steinberg, Jonathan S. — University of Rochester
- Study coordinator: Steinberg, Jonathan S.
Related research
Other NIH-funded projects on the same topics.
-
Insertable heart monitor to catch early atrial fibrillation after catheter ablation
This trial tests whether a small implanted heart monitor that finds early, often-silent atrial fibrillation and prompts early treatment can help people with drug-resistant atrial fibrillation after catheter ablation.
-
Using a heart monitor to improve treatment outcomes for atrial fibrillation after catheter ablation
This study is looking at how a small heart monitor can help catch early signs of atrial fibrillation returning after treatment, so that people can get the right help sooner, and it’s for patients who have had catheter ablation for this condition.
-
Using advanced imaging techniques to improve heart procedure outcomes for atrial fibrillation
This study is looking to make catheter ablation for atrial fibrillation more effective by using advanced imaging techniques to better understand heart anatomy, which could help doctors personalize treatment plans and improve results for patients like you.
-
Cardiomyocyte-fibroblast signaling in atrial fibrillation
A researcher at Baylor College of Medicine is studying how signals between heart muscle cells and supportive heart cells influence atrial fibrillation, with the goal of finding new ways to prevent or treat this common heart rhythm problem.
-
Anticoagulation in ICH Survivors with Atrial Fibrillation and Small Vessel Disease
This project looks at how to safely use blood-thinning medicines in people who survived a brain bleed and also have atrial fibrillation and small vessel disease.
-
Lowering heart inflammation to reduce atrial fibrillation risk in people with diabetes
Seeing whether blocking a pro-inflammatory enzyme or boosting the heart's natural inflammation-resolving signals can lower atrial fibrillation risk in people with diabetes.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.